Emcure Pharmaceuticals' Emcutix Acquires Exclusive Rights to Sell PRX-Plus in India Under Licensing Agreement with WiQo

Emcure Pharmaceuticals, one of the Indian pharma industry's top names, has reported that its dermatology business unit, Emcutix, has acquired exclusive rights for selling PRX-Plus in India. The achievement has come as part of an exclusive licensing agreement inked between Emcutix and Italian brand WiQo, recognized for its novel aesthetic and dermatological products.

 

Highlights:

Leadership Observations

A spokesperson at Emcure said, "This tie-up with WiQo shows our intent to bring world-class innovations to the Indian market. We are looking forward to the potential of PRX-Plus to change the skincare solutions landscape."

 

Outlook:

This deal makes Emcure a significant contributor to India's growing dermatology and aesthetics industry.

 

Sources: Business Standard, Economic Times; April 1, 2025